Literature DB >> 18346142

The effect of adding oral dexamethasone to feed alterations on the airway cell inflammatory gene expression in stabled horses affected with recurrent airway obstruction.

L DeLuca1, H N Erb, J C Young, G A Perkins, D M Ainsworth.   

Abstract

BACKGROUND: Chemokine expression in airway epithelium and bronchoalveolar lavage fluid (BALF) cells of horses with recurrent airway obstruction (RAO) is increased. HYPOTHESIS: For RAO-affected horses that are stabled and fed a pelleted ration, the addition of oral dexamethasone further improves pulmonary function and reduces inflammatory gene expression in pulmonary cells. ANIMALS: Twelve RAO-affected horses.
METHODS: In a randomized cross-over experiment, the effect of feeding pellets in lieu of hay to stabled, RAO-affected horses was compared with the effect of feeding pellets and administering a 21-day decreasing dose regimen of oral dexamethasone on the expression (by kinetic polymerase chain reaction) of interleukin-8 (IL-8), chemokine (C-X-C motif) ligand 2 (CXCL2), IL-1beta, IL-6, and beta-actin in the BALF cells and of IL-8, CXCL2, 2 IL-1 receptor (IL-1R2), Toll-like receptor 4 (TLR4), and glyceraldehyde 3-phosphate dehydrogenase in the bronchial epithelium 2 days after the final dose.
RESULTS: Both treatments reduced airway neutrophilia and breathing efforts but the addition of dexamethasone was associated with fewer treatment failures. Compared with feed changes alone, dexamethasone administration further reduced the expression of IL-8, CXCL2, and IL-1beta in the BALF cells 3.3-, 2.5-, and 4.7-fold, respectively. In the airway epithelium, both treatments were equally efficacious in reducing the expression of IL-8 and CXCL2 expression relative to pretreatment values, but either treatment failed to alter the expression of IL-1R2 and TLR4. CONCLUSIONS AND CLINICAL IMPORTANCE: For a rapid and consistent improvement in pulmonary function and a reduction in inflammatory gene expression of the BALF cells, a decreasing dose of oral dexamethasone in combination with feed alterations is more efficacious for horses that must remain stabled.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346142     DOI: 10.1111/j.1939-1676.2008.0055.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  6 in total

1.  Differential gene expression and Ingenuity Pathway Analysis of bronchoalveolar lavage cells from horses with mild/moderate neutrophilic or mastocytic inflammation on BAL cytology.

Authors:  Kaori Uchiumi Davis; M Katie Sheats
Journal:  Vet Immunol Immunopathol       Date:  2021-02-04       Impact factor: 2.046

2.  Evaluation of suitable reference genes for gene expression studies in bronchoalveolar lavage cells from horses with inflammatory airway disease.

Authors:  Laura Beekman; Triin Tohver; Rkia Dardari; Renaud Léguillette
Journal:  BMC Mol Biol       Date:  2011-01-28       Impact factor: 2.946

3.  Inflammatory Airway Disease of Horses--Revised Consensus Statement.

Authors:  L L Couëtil; J M Cardwell; V Gerber; J-P Lavoie; R Léguillette; E A Richard
Journal:  J Vet Intern Med       Date:  2016-01-24       Impact factor: 3.333

4.  Effect of injected dexamethasone on relative cytokine mRNA expression in bronchoalveolar lavage fluid in horses with mild asthma.

Authors:  Stephanie L Bond; Jana Hundt; Renaud Léguillette
Journal:  BMC Vet Res       Date:  2019-11-06       Impact factor: 2.741

Review 5.  Equine asthma: Integrative biologic relevance of a recently proposed nomenclature.

Authors:  Stephanie Bond; Renaud Léguillette; Eric A Richard; Laurent Couetil; Jean-Pierre Lavoie; James G Martin; R Scott Pirie
Journal:  J Vet Intern Med       Date:  2018-10-07       Impact factor: 3.333

6.  Effect of intrabronchial administration of autologous adipose-derived mesenchymal stem cells on severe equine asthma.

Authors:  Neža Adamič; Sonja Prpar Mihevc; Rok Blagus; Petra Kramarič; Uroš Krapež; Gregor Majdič; Laurent Viel; Andrew M Hoffman; Dorothee Bienzle; Modest Vengust
Journal:  Stem Cell Res Ther       Date:  2022-01-21       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.